Minocycline is an antibiotic now recognized to have antiapoptotic and antiinflammatory properties. Because of these properties, minocycline may be of benefit in reducing neuronal apoptosis from ischemia and subsequent postischemic inflammation if administered soon after a stroke. We now explore the feasibility of using 99m Tc-annexin V, an in vivo marker of apoptosis, with SPECT to monitor the antiapoptotic effects of minocycline therapy. Methods: CB6/F1 adult male mice underwent unilateral distal middle cerebral artery occlusion (dMCA) occlusion and were imaged and sacrificed at 1, 3, 7, or 30 d after injury. Animals were given minocycline (or vehicle) 30 min and 12 h after dMCA occlusion and then given 22.5 mg/kg twice daily for up to 7 d. Before imaging, behavioral tests were performed to evaluate the neurologic function. After imaging, brains were collected for histology and assessed for the degree of apoptosis and microglial activation. Results: 99m Tc-Annexin V uptake in injured hemispheres was significantly decreased 2-to 3-fold by minocycline at all time points. Minocyline reduced infarct size as seen histologically and improved behavioral indices as late as 30 d. Infarct volume as seen histologically correlated with radiolabeled annexin V uptake seen by SPECT. In situ fluorescent microscopy demonstrated that annexin V bound primarily to neurons at 1 and 3 d, with a shift toward microglia by 7 and 30 d. Conclusion: We found that minocycline significantly reduces neuronal apoptosis and infarct size and improves neurologic outcome in mice after acute focal cortical ischemia. Apopt osis has been found to play an important role in postischemic cell death and postischemic inflammation (1,2). This observation has spawned the development of new specific antiapoptotic neuroprotective drugs (3). Minocycline is a member of the tetracycline family of antibiotics with recently recognized antiapoptotic and antiinflammatory properties. The antiapoptotic properties of minocycline appear to be due to its ability to inhibit caspase-3 (4), whereas its antiinflammatory effect appears to be due to a mechanism inhibiting p38 MAPK (MAPK is mitogen-activated protein kinase) activation in microglia (5). As such, minocycline has thus been shown to protect the brain against ischemic insults (6,7) and improve functional impairment (8). Apoptosis can be imaged indirectly with radiolabeled annexin V in animal models and humans using SPECT. Annexin V is a human protein that has a high affinity for the membrane anionic phospholipid phosphatidylserine (PS), which is selectively exposed after activation of caspase-3 (9-11). In the current study, we apply annexin V SPECT to monitor the treatment response to minocycline treatment of mice subjected to an acute unilateral distal middle cerebral arterial (dMCA) ischemic injury.
Apopt osis has been found to play an important role in postischemic cell death and postischemic inflammation (1, 2) . This observation has spawned the development of new specific antiapoptotic neuroprotective drugs (3) . Minocycline is a member of the tetracycline family of antibiotics with recently recognized antiapoptotic and antiinflammatory properties. The antiapoptotic properties of minocycline appear to be due to its ability to inhibit caspase-3 (4), whereas its antiinflammatory effect appears to be due to a mechanism inhibiting p38 MAPK (MAPK is mitogen-activated protein kinase) activation in microglia (5) . As such, minocycline has thus been shown to protect the brain against ischemic insults (6, 7) and improve functional impairment (8) . Apoptosis can be imaged indirectly with radiolabeled annexin V in animal models and humans using SPECT. Annexin V is a human protein that has a high affinity for the membrane anionic phospholipid phosphatidylserine (PS), which is selectively exposed after activation of caspase-3 (9-11). In the current study, we apply annexin V SPECT to monitor the treatment response to minocycline treatment of mice subjected to an acute unilateral distal middle cerebral arterial (dMCA) ischemic injury.
MATERIALS AND METHODS

Murine Model of Experimental Stroke
CB6/F1 male mice (Jackson Laboratories), 25-30 g, were housed and treated in a humane manner in strict accordance with institutional guidelines. Ninety-nine mice were used for this study. Two mice were used as sham controls for the behavior assays, and their brains were collected to use as negative controls for the histology/ immunostains. Forty-four mice were scanned using SPECT and were harvested at various times for histology and other assays. Fiftyone mice were used for the behavior studies, and brains were harvested at various times for histology and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) stains (detailed numbers by time point are broken down in the individual figures). Mice were anesthetized with 5% isofluorane delivered into an anesthesia induction chamber with oxygen and air supplied at a ratio of 0.2 L/min oxygen:0.8 L/min air. Once surgical planes of anesthesia were attained (assessed by absence of hind leg withdrawal to pinch), isoflurane was decreased to 2%-2.5% throughout the remainder of the surgery. The dMCAwas occluded as previously described by Zhao et al. (12) with some modifications. Briefly, a cervical midline incision was made to expose both common carotid arteries (CCAs). The animal was then placed on its right side and a 1-cm vertical skin incision was made in the midpoint between the left orbit and the external auditory canal. The temporalis muscle was bisected and a 1-mm burr hole was made at the junction of the zygomatic arch and the squamous bone, and the dMCAwas exposed at the rhinal fissure. The dMCA superior to the rhinal fissure was then occluded by a bipolar electric coagulator. The animal was then placed in the supine position, and both CCAs were temporarily occluded with aneurysm clips for 45 min. Clips were then removed and wounds were closed and animals were then allowed to recover. Mice received 45 mg/kg minocycline HCl (Sigma), dissolved in 0.01 M phosphate-buffered saline (PBS), intraperitoneally 30 min and 12 h after MCA occlusion and from then on received 22.5 mg/kg twice a day for up to 7 d; controls received PBS as vehicle.
Animals also underwent small-animal SPECT at 1, 3, 7, or 30 d after ischemic injury. After imaging, animals were sacrificed with an overdose of isoflurane. Immediately after sacrifice, brains were carefully removed for histology and other immunohistochemical assays.
Behavior Studies
All sensorimotor functional assessments were performed by investigators who were unaware of treatment groups.
Corner Test. The corner test was performed using the methodology as developed by Li et al. (13) . Briefly, 2 sheets of cardboard (each 20 · 30 · 1 cm) were placed in the home cage of the animal and positioned to create a 30°corner with a 0.5-to 1-cm gap to permit light to shine through. The animal was placed between the boards and encouraged to enter the corner. Once the animal reached the corner, the vibrissae were stimulated bilaterally by the cardboard sheets, causing the animal to rear forward and upward, and finally to turn around and face the open end of the boards. Each animal was serially tested 20 times and the number of turns toward the ipsilateral ischemic hemisphere (left) were counted.
Ladder Test. Another measure of sensorimotor function used in this study was the ladder test (14) with minor modifications. A ladder composed of 40 rungs with a 1-mm diameter and 2-cm intervals was constructed. The ladder was placed between 2 transparent acrylic walls spaced 4 cm apart, so that once the mouse was placed on the ladder, it could only move straight ahead. The ladder was placed at a 45°slope and the animal was encouraged to move forward and upward. Each weight-bearing step was recorded by a video camera placed underneath the ladder. The number of forelimb faults associated with each-weight bearing were then reviewed and tabulated.
Infarct Volume Assessment
After mice were euthanized and perfused, brains were removed and sunk in 20% sucrose at 4°C for 24-48 h. Cryosections (25-mm thick) were prepared from brains of animals that survived 1 and 3 d and stained with cresyl violet. Infarct volume was determined using previously published methods (15) . Brains of animals that survived 7 and 30 d were stained with hematoxylin and eosin, as cresyl violet does not reliably delineate regions of infarction by 7 d.
Histochemistry
Brain sections were fixed with 75% acetone/25% ethanol for 15 min and then blocked in 5% normal goat serum, 5% normal horse serum, and 1% bovine serum albumin in PBS. Sections were reacted with primary antibodies conjugated to a fluorescent probe overnight at 4°C in a foil-wrapped box. Neurons were detected by mouse antineuronal nuclei (NeuN) conjugated to Alexa Fluor 488 (1:100, MAB377X, mouse monoclonal; Chemicon); astrocytes were detected by antiglial fibrillary acidic protein (GFAP) conjugated to Alexa Fluor 488 (1:200, A-21294, mouse monoclonal; Invitrogen); microglia were detected by fluorescein isothiocyanate (FITC)-conjugated isolectin B4 from Bandeiraea simplicifolia (IB4, 20 mg/mL, L2895; Sigma) or tomato lectin conjugated to FITC (lectin, 20 mg/mL, L0401; Sigma). After washing, sections were incubated in annexin V conjugated to Cy3.18 from human placenta (1:100 diluted in a solution of 100 mM N-(2-hydroxyethyl)piperazine-N9-(2-ethanesulfonic acid) [HEPES]/NaOH, pH 7.5, 1.4 M NaCl, and 25 mM CaCl 2 , A4963; Sigma). To delineated areas of annexin V binding, FITC-labeled annexin V was applied directly to brain sections (1:100 dilution containing 100 mM HEPES/NaOH, pH 7.5, 1.4 M NaCl, and 25 mM CaCl 2 , A9210; Sigma) or injected into animals 1 h before sacrifice (100 mg/kg protein per animal, intraperitoneally). Brain sections were mounted with VectaShield Mounting Medium with 4,6-diamino-2-phenylindole (DAPI) (H-1200) and visualized under a fluorescent microscope (Axiovert 40 CFL; Carl Zeiss).
To identify microglia and other cells of monocyte lineage, adjacent brain sections were stained with horseradish peroxidaseconjugated IB4 (20 mg/mL; Sigma) using a previously published protocol (16) .
TUNEL Staining
TUNEL staining was performed with the ApopTag peroxidase in situ apoptosis detection kit (S7100; Chemicon) according to kit instructions. Cryosections were fixed in 1% paraformaldehyde and then treated with precooled ethanol/acetic acid, 2:1, for 5 min at 220°C and then incubated in 3% hydrogen peroxide followed by incubation at 37°C in terminal deoxynucleotidyl transferase enzyme for 1 h. Sections were reacted with antidigoxigenin peroxidase conjugate for 30 min at room temperature and developed in peroxidase substrate. Sections were counterstained with methyl green.
Cell Counting
The number of IB4-positive cells within 6 high-power fields (·400) of the periinfarct area was counted as described previously (16) . Typically, microglia form a distinct dense band surrounding the ischemic lesion, permitting some consistency in defining the periinfarct region from animal to animal. For TUNEL-stained sections, all TUNEL-positive cells as well as TUNEL-positive cells with morphologic criteria consistent with apoptosis (17) were counted within the same periinfarct regions as the IB4 counts. The number of positive cells in 6 consecutive fields around the striatum and cortex at ·400 magnification was counted. Each section was counted 3 times and averaged. Three sections were analyzed in each group of mice. All counts were performed by an experienced observer who was unaware of the treatment groups.
Preparation of Radiolabeled Annexin V
NAS 2020 kits were generously supplied by Theseus Imaging Corp. The 2-vial kit includes a vial of 0.5 mL (0.25 mg) of frozen liquid hydrazinonicotinamide-recombinant human (HYNIC-rh)-annexin V conjugate solution (vial 1) and a vial of lyophilized stannous tricine containing approximately 20 mg tricine and 500-650 mg stannous chloride (vial 2). Radiolabeling was conducted at room temperature. 99m Tc-Pertechnetate (1,110-1,850 MBq [30-50 mCi]; 0.4-0.6 mL) was added to the HYNIC-rh-annexin V conjugate (vial 1). The lyophilized stannous tricine (vial 2) was reconstituted with 3 mL of sterile saline. Then, an aliquot of 0.3 mL of stannous tricine solution was added to the HYNIC-rhannexin V vial. The vial was mixed gently, allowed to incubate at room temperature, diluted by the addition of 2 mL sodium chloride for injection, and tested for quality by visual inspection, pH, and radiochemical purity testing with instant thin-layer chromatography (ITLC) silica gel and acid citrate/dextrose (ACD) solution and pH strips necessary for the quality control of the product. Radiochemical purity of the drug product was verified to be .90% as determined by ITLC (ACD).
Small-Animal SPECT
Before imaging, animals were sedated for imaging with 0.1 mL of a cocktail of ketamine (24 mg/mL)/xylazine (3 mg/mL) in PBS injected intraperitoneally. Images were obtained using the LumaGEM small-animal SPECT system (Gamma Medica Instruments). This system is equipped with a single-head detector with a maximal 13 · 13 cm field as well as a maximal resolution of 0.4 mm with a 1-mm pinhole collimator. SPECT images were recorded into a 64 · 64 imaging matrix for the projection data (and 64 3 for the ordered-subsets expectation maximization reconstructed data), 3°per step, 30 s per step for a 360°rotation with a radius of rotation of 2.0 cm. Animals were administered 1852370 MBq (5210 mCi) of 99m Tc-HYNIC-annexin V (20-50 mg/kg of protein) 1 h before imaging by penile vein injection. Pinhole data reconstruction was performed using the software and methods described previously (11) . To define the activity distribution in the brain in our SPECT data, we have developed tools for the analysis of 3-dimensional images consisting of parametric 3-dimensional regions of interest (ROIs), interactively placed and sized. Typical regions used were spheric regions with shells that were spheric or ellipsoid.
Two ROIs were drawn within the cerebral hemispheres of each animal: one that circumscribed the ischemic lesion of the left cerebral cortex and the other placed within the contralateral hemisphere used as background activity (BKG) for subsequent calculations. The total number of counts, adjusted for volume, was summed between the 34th and 68th percentiles determined from the histograms of both the lesion and BKG ROIs. The total number of counts per voxel for each lesion was then normalized by dividing by the number of counts per voxel of the respective BKG ROI. This ratio was then multiplied by the fractional lesion volume (relative to the total volume of the cerebral hemispheres) to obtain the total normalized lesion activity for each SPECT examination.
Statistical Analysis
All statistical analyses were performed using Sigma Stat 2.03 (Systat Software, Inc.). Quantitative data are presented as mean 6 SE. Two-group comparisons were performed by a 2-tailed Student t test. Multiple-group comparisons were performed using 1-way ANOVA followed by the Tukey HSD (honestly significant difference) post hoc test. x 2 or nonparametric tests were used for noncontinuous data. P , 0.05 was considered statistically significant.
RESULTS
Minocycline Reduces Infarct Volume
In the control groups, the infarct volume, as seen histologically, increased from 1 to 7 d after the experimental stroke but, by 30 d, the infarct volume decreased to that seen in the 1-d group. Infarct sizes in the 7-d group were larger infarcts than the 1-, 3-, and 30-d groups (Fig. 1C) . Minocycline reduced infarct volume at all time points compared with vehicle-treated controls (Figs. 1A and 1C ).
Minocycline Improves Sensorimotor Function
Treatment with minocycline significantly improved sensorimotor function as measured by the corner and ladder tests. For the corner test, minocycline-treated animals showed less frequent turning to the lesion side than the control animals at 3, 7, and 30 d after ischemia. Shamoperated animals showed no difference in turning between sides ( Fig. 2A) . For the ladder test, minocycline-treated animals showed fewer forelimb faults at 3, 7, and 30 d after the stroke than the control mice (Fig. 2B) . Sham-operated animals had few, if any, foot faults (data not shown).
Annexin V SPECT Uptake
Minocycline reduced annexin V uptake by 2-to 3-fold at each time point. Annexin V uptake was maximal on days 1 and 7, with a relative trough on day 3 in both control and minocycline-treated groups. This was followed by a decline at 30 d below day 3 values in both groups. (Figs. 1B and 1D) 
Localization of Annexin V Binding
Because annexin V could bind internal PS residues exposed by cryosectioning if applied directly to brain sections, we compared the direct application of labeled annexin to tissue sections versus injecting animals with annexin before euthanasia. In brains of uninjured mice, FITC-labeled annexin V, when applied directly to brain sections or when injected into animals 1 h before sacrifice (100 mg/kg protein per animal, intraperitoneally), showed similar staining patterns. As shown in Figures 3A and 3B , the binding pattern is similar with both methods. Some background staining is present with occasional punctuate binding to intracellular structures in both cases. In contrast, annexin V applied directly to brain sections in mice subjected to stroke revealed positive cells with delineation of the entire cell (Fig. 3B) . Therefore, for double-labeling studies, we chose to apply labeled annexin V directly to tissue sections. Ischemic brain sections were costained with Alexa Fluor 488-conjugated Neun, GFAP, or FITC-labeled tomato lectin (which tends to identify all cells of monocyte lineage compared with IB4, which tends to stain activated cells more robustly), plus Cy3.18-conjugated annexin V. Doublelabeled cells in 6 consecutive fields within the periinfarct area were counted at ·400. One and 3 d after the stroke, annexin V colocalized primarily to Neun-positive cells (43% 6 13.4% and 59% 6 12.5%, respectively). At later time points (i.e., 7 and 30 d after stroke), fewer neurons bound annexin V. On 7 and 30 d after the stroke, annexin V colocalized primarily to lectin-positive cells (55% 6 5% and 49% 6 11%, respectively). Astrocytes, on the other hand, rarely bound annexin V at any time point (Figs. 3C  and 3D ).
Minocycline Treatment Reduces Apoptosis and Inflammation
Minocycline treatment significantly reduced the number of TUNEL-positive cells as well as TUNEL-positive cells displaying characteristic nuclear morphology of apoptosis (Figs. 4A and B) . IB4 staining showed that microglia/ monocytes/macrophages increased in number, reaching a peak 7 d after a stroke. This was also significantly reduced by treatment with minocycline (Fig. 5) .
DISCUSSION
Minocycline, a member of the tetracycline family of antibiotics, has been shown to reduce injury due to cerebral ischemia via several antiinflammatory and antiapoptotic actions (6, 7, 18, 19) . These include the inhibition or reduction of the metalloproteinase MMP-9 (6), caspase-3, oxidative stress (20) , cytochrome c translocation (21) , and p38 MAPK activity (5, 22) . In a previous study we have also shown that minocycline can prevent microglial activation and not only reduce infarct size after an experimental stroke but also limit BBB disruption and hemorrhage (18) .
In the current study animals treated with minocycline for 1 wk showed significant improvement of neurologic function that persisted as far out as 30 d. Infarct volume was also reduced up to 30 d. These observations are in line with those by Liu et al. (8) , who found improvement in functional deficits when minocycline treatment was delayed 4 d after stroke onset, and animals survived 6 wk. These results are different from those of a study of neonatal stroke in which only a temporary protection by minocycline was Each mouse was tested 3 times and counts were averaged. Minocycline-treated animals (black bars) showed fewer forelimb faults per 100 steps than vehicle-treated mice (white bars) (*P , 0.05).
observed (22) . The transient benefits of minocycline in the neonatal rodent model may be related to the short period of minocycline treatment used in the study or inherent differences in the immature brain compared with the adult brain.
We previously showed that 99m Tc-labeled annexin V uptake correlated with neuronal apoptosis after a stroke (9, 10) . In this study we have extended our period of observation to 30 d after a stroke and have further defined the cell types that bind annexin V. Our data have shown that there is a shift in the proportion of annexin V2binding cells from predominately neurons at 24 h to microglial cells 7 d after a stroke. The peak annexin V uptakes seen on day 1 and day 7 correlate with the peak number of doubly stained neurons and microglial cells, respectively. The trough on day 3 appears to represent an intermediate time point in which apoptotic neurons disappear and microglial cells begin to infiltrate and proliferate in the penumbra of Comparison of annexin V staining when substrate was applied directly to tissue sections (A) or injected into animals 1 h before sacrifice (B) (100 mg/kg protein per animal, intraperitoneally). The annexin V binding pattern (green) for both methods is similar, with some background staining and staining of some intracellular organelles seen in both. Clearly, the staining pattern in both methods is distinct from that seen after ischemia (C) (DAPI, blue). (C) Representative images of annexin V binding to different types of cells after ischemia. Brain sections were stained with Alexa Fluor 488-conjugated Neun, GFAP, or FITClabeled tomato lectin (n 5 5/group) and then colabeled with annexin V conjugated to Cy3.18. Three days after stroke, annexin V bound primarily neurons (Neun, arrowheads), whereas 30 d after stroke, annexin V bound microglia (Lectin, arrows). Rare astrocytes (GFAP) bound annexin V (representative image shown here 7 d after stroke). (D) Annexin V binds neurons acutely and microglia subacutely after experimental stroke. Double-labeled cells in 6 consecutive nonoverlapping ·400 fields within periinfarct zone were counted and expressed as fraction of all cells labeled for the respective cell-type marker. One and 3 d after stroke, annexin V bound primarily neurons (solid line) but, at later time points (7 and 30 d), annexin V bound primarily microglia/monocytes (dashed line). There were few annexin V2positive astrocytes, and this pattern did not change over time (dashed2dotted line). *P , 0.05, **P , 0.01 vs. other cell types at a given time point. (A-C, scale bar 5 75 mm).
an infarct. The high annexin uptake seen on day 7 is most likely due to microglial apoptosis that is part of the normal regulation of the immune system. Astrocytes did not display a significant degree of annexin V binding in our stroke model. Annexin V imaging, though not specific to cell type, was able to assess the temporal changes in overall apoptosis after ischemic injury. These data suggest that 99m Tc-labeled annexin V SPECT detects primarily neuronal cell death up to 3 d after a stroke, after which annexin V binds primarily inflammatory cells. Several methods have been used to detect ischemia at the clinical level, and recent work in the area of stroke research has focused on apoptosis and inflammation as being critical events ultimately leading to brain cell death. Although these processes can be detected routinely in the laboratory, this is not always possible using available imaging methodologies. 99m Tc-Labeled annexin V SPECT has already been studied to monitor apoptosis in oncotherapy (23, 24) and transplantation (25) . In our previous work, we showed that treatment with an antiapoptotic therapy (antibody against Fas ligand) reduced injury in a rodent stroke model, and this was correlated with decreased annexin uptake using SPECT. We also used this technique to detect apoptosis in stroke patients to show that in patients imaged within 8 h of symptom onset, SPECT of radiolabeled annexin V showed binding within regions of ischemia detected by diffusion-weighted MRI (11) .
CONCLUSION
We show that minocycline, an antibiotic with antiapoptotic and antiinflammatory properties, improves long-term outcome after an experimental stroke. Furthermore, we show that 99m Tc-labeled annexin V SPECT can be used as a noninvasive tool to monitor apoptosis in the acute and subacute stages of stroke and the brain's response to potential therapy.
